2 Financial Stocks Rising on Big Volume

DELAFIELD, Wis. (Stockpickr) -- Professional traders running mutual funds and hedge funds don't just look at a stock's price moves; they also track big changes in volume activity. Often when above-average volume moves into an equity, it precedes a large spike in volatility.

>>5 Stocks Insiders Love Right Now

Major moves in volume can signal unusual activity, such as insider buying or selling -- or buying or selling by "superinvestors."

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst. These types of traders like to get in well before a large spike, so it's always a smart move to monitor unusual volume. That said, remember to combine trend and price action with unusual volume. Put them all together to help you decipher the next big trend for any stock.

>>5 Stocks Set to Soar on Bullish Earnings

With that in mind, let's take a look at several stocks rising on unusual volume today.

Home Properties

Home Properties (HME) is a real estate investment trust that owns, operates, acquires, develops and rehabilitates apartment communities mainly in selected Northeast and Mid-Atlantic regions of the U.S. This stock closed up 4.6% at $55.49 in Wednesday's trading session.

Wednesday's Volume: 1.55 million

Three-Month Average Volume: 389,694

Volume % Change: 285%

From a technical perspective, HME ripped sharply higher here right off some near-term support at $52.39 with strong upside volume. This stock has been downtrending over the last month and change, with shares falling from its high of $60.88 to its low of $52.39. During that move, shares of HME have been consistently making lower highs and lower lows, which is bearish technical price action. That said, the spike higher on Wednesday in HME has now moved the stock out of its downtrend, and it's pushed shares within range of triggering a near-term breakout trade. That trade will hit if HME manages to take out some near-term overhead resistance levels at $56.17 to its 50-day moving average of $56.77 with high volume.

Traders should now look for long-biased trades in HME as long as it's trending above $54 or $53 and then once it sustains a move or close above those breakout levels with volume that this near or above 398,694 shares. If that breakout hits soon, then HME will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day of $60.13 to $60.88. Any high-volume move above $60.88 will then give HME a chance to tag $63 to $64.

Apollo Global Management

Apollo Global Management (APO) is an alternative asset management company. This stock closed up 2.1% at $30.02 in Wednesday's trading session.

Wednesday's Volume: 2.19 million

Three-Month Average Volume: 1.01 million

Volume % Change: 117%

From a technical perspective, APO

Traders should now look for long-biased trades in APO as long as it's trending above Wednesday's low of $16.41 or above more support at $16.10, and then once it sustains a move or close above its 52-week high at $18.28 with volume that hits near or above 247,612 shares. If that breakout hits soon, then SWIR will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $22 to $25.

To see more stocks rising on unusual volume, check out the Stocks Rising On Unusual Volume portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.

RELATED LINKS:

>>4 Stocks Under $10 Moving Higher

>>4 Stocks Rising on Big Volume

>>5 Hated Earnings Stocks You Should Love

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

JPMorgan feels Twitter's doubled-edged sword

It was only a week ago that JPMorgan Chase helped launch the wildly successful Twitter IPO, and one can't help but wonder if executives at the financial services conglomerate are now wishing they had never heard of the popular microblogging site.

While the IPO went well, JPMorgan's effort this week to tap into the fresh social media hype with an ill-conceived Twitter-based Q&A session is already being described as a case study in how not to use social media.

Hours after promoting a live one-hour Q&A session with vice chairman James B. Lee Jr. using the hashtag #AskJPM, the session, scheduled for today, was cancelled when it became clear that the mood of the vast cyber universe was swinging from sarcastic to angry and back.

A story by DealBook yesterday detailed the initial reaction from Twitter users to JPMorgan's open-ended offer to answer questions.

But the hits just keep on rolling across Twitter with funny, nasty, and sometimes crude references to JPMorgan's recent challenges.

This afternoon @RacehorseDC asked, “What does it feel like when crime does pay?”

And @ddayen wants to know, “What's more satisfying: securities fraud on pension fund investors, or foreclosing on all those Alt-A loans?”

Then, of course there is @JohnBrubaker who wants to know, “Where do I apply for the now vacant PR job at your firm?”

JPMorgan has been mostly silent since cancelling the Q&A session, but a company spokesperson did respond to an email request for comment with the following: “#BadIdea! Back to the drawing board.”

It's nice to see the company still has its sense of humor, but the drawing board would have been a great place to start before turning to something as unconstrained as Twitter with such a wide-open offer.

“I would have to assume that JPMorgan is not tapped into enough of their audience,” said Ted Birkhahn, president of Peppercomm, a marketing and communications firm. "If they had taken a minute to think about how their audiences are thinking about them these days, they probably would not have gone through with trying to promote a Twitter Q&A.”

Mr. Birkhahn said the first mistake was trying to set up Mr. Lee to communicate via the company Twitter account instead of his own account, which would have made it seem a lot more like a real conversation.

“Using an individual Twitter handle is inviting people in to talk directly with an individual,” he said. “In order to operate on Twitter, you as the individual should be active and familiar to the Twitter audience, and I don't think that's the case here with James Lee.”

The JPMorgan spokesperson person, who asked not to be identified, assured me that Mr. Lee ! does have his own Twitter account, but did not respond when I asked what his handle is, and I couldn't find it through my searches.

“Not establishing the parameters of the discussion and opening the floor for anything and everything that anyone wanted to ask is a recipe for disaster in social media,” Mr. Birkhahn said. “Of course, even being specific doesn't prevent the audience from going off on tangents, but that goes back to knowing your audience.”

A Formula That Predicts Your 401(k) Earnings

How much can you pile up in your retirement account, if you start contributing when you're young? I have a formula that will give you a pretty good idea of likely returns over a long period. The answer: Compound growth delivers nice results, but maybe not as nice as you were counting on.

Here's the formula for the expected annual return, in percentage points, from a collection of stocks and bonds:

r = 5*S + 2*B – E

The return r is a real return, which is to say, the return net of inflation. S is the fraction of your portfolio in stocks, B the fraction in bonds, E the expenses taken off the top.

Example: You invest in a typical 60/40 mix of stocks and bonds, and the funds you are invested in have an average expense ratio of 0.8%. Then you can look forward to a 3% compound return, over a long period: 3 = 5*0.6 + 2*0.4 – 0.8.

Perhaps you were thinking of something a little richer than that? More like 7%? The promoters of retirement saving like to provide wondrous illustrations of the power of compound interest. Put away a buck when you're 27, let it sit for four decades, and a 7% return will turn it into $15. With compounding like that, you could amass upwards of $1 million for retirement from just four years of maximum 401(k) contributions at $17,500 per year.

Numbers like those are misleading, even if offered in the good cause of motivating workers to save. There are three things wrong with a 7% return assumption.

The first is that not many people can afford to take the risk of an all-stock, all-the-time portfolio. Stocks are likely to beat bonds over any long period, but it is not certain that they will. Stocks could have a 40-year bad patch. Japan is in the middle of one of those; its stocks are off sharply from their 1989 highs, and a young Japanese saver who ventured into the market 24 years ago will be lucky to have broken even over the period 1989-2029.

The second source of disillusionment for someone expecting 7% is inflation. If you retire in 2053, you will be buying things at 2053 prices with your savings. I think 2% is a reasonable forecast for inflation. Prices have gone up a bit less than that in the past year but surely the day will come when we pay for the Federal Reserve's money printing habits.

Subtract 2% from a nominal 7% total return (dividends plus appreciation) on stocks and you get the 5% real return used in the formula for stocks.

Bonds are in the formula with an expected 2% real return. Can you get that from fixed income? Maybe, provided that you include riskier bonds in the mix. If you stick to safe Treasury bonds you'll get less: The 20-year TIPS (inflation-adjusted security) has a real yield to maturity of 1%. High-grade corporates yield close to 4% these days in nominal terms and might net you close to 2% after inflation. Junk bonds and convertible bonds, at the risky end of fixed income, could give you a 3% real return.

Item three on the bad news agenda is fees. An annual cost of 0.8% is par for the course in retirement plans. If you work for a small company that doesn't pay attention to costs you might lose twice that to fees. A big 401(k) plan run by frugal managers might have average expenses around 0.3%.

You can do still better than that, if you have a plan with a brokerage window. Use it to buy cheap ETFs. For U.S. stocks, broad-market funds from Vanguard and Schwab (tickers: VTI and SCHB) are bargains. For foreign stocks, these same vendors offer VEA and SCHF. In fixed income, the iShares and Vanguard products are cheap (AGG and BND). Usually, it doesn't make sense to do a trade unless you're moving at least $20,000, so use other options, like  no-load mutual funds, while smaller sums accumulate.

What about cash? Historically it has had a real return of zero, meaning that the yield on Treasury bills just about ties the inflation rate. At the moment cash has a negative real return. My formula assumes, charitably, that it will claw its way back up to zero fairly soon. Over the long term your cash position will do you little harm and little good. You shouldn't have any of your retirement account sitting idle.

Consider a hypothetical saver named Sally, with a 401(k) invested 50% in stocks, 30% in bonds and 20% in cash. The cash can be ignored. The other two components together yield her an expected real return of 5*0.5 plus 2*0.3 percentage points. That's before expenses. If Sally is coughing up 0.5% of invested assets per year to the fund managers—which comes out to 0.4% of her total account assets—then she can look forward to a 2.7% annual growth.

Over 40 years, her $17,500 of postponed consumption will not quite triple in spending power to the equivalent of $50,800 of today's money. That's good, but nothing like the 15-fold gain she might be dreaming of if she looked at some projection using a 7% return.

Insiders Are Buying Retrocom Real Estate Investment Trust

One real estate investment trust has seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:

The stock is purchased by three or more insiders within one month.

The stock is sold by no insiders in the month of intensive purchasing.

At least two purchasers increase their holdings by more than 10%.

Retrocom Real Estate Investment Trust (TSX:RMM.UN), formerly Retrocom Mid Market Real Estate Investment Trust, is an open-ended real estate investment trust (REIT). Its portfolio of retail properties is geographically diversified across Canada.

[ Enlarge Image ]

Insider Buying During the Last 30 Days
Christopher Cann purchased 2,750 shares on Sept. 24 and currently controls 25,000 shares or less than 0.1% of the company. Christopher Cann serves as a director of the company. Christopher Cann increased his holdings by 12.4% in September.Patrick Lavelle purchased 5,000 shares on Sept. 20 and currently holds 83,270 shares or 0.1% of the company. Patrick Lavelle is chairman of the board. Patrick Lavelle increased his holdings by 6.4% in September.David Schiffer purchased 1,060 shares on Sept. 6 and currently holds 6,660 shares or less than 0.1% of the company. David Schiffer serves as a director of the company. David Schiffer increased his holdings by 18.9% in September.Insider Buying by Calendar Month

Here is a table of Retrocom REIT's insider-trading activity by calendar month.

Month	Insider buying / shares	Insider selling / shares
September 2013	8,810	0
August 2013	20,000	0
July 2013	0	0
June 2013	0	0
May 2013	65,900	0
April 2013	0	0
March 2013	0	0
February 2013	0	0
January 2013	0	0

There have been 94,710 shares purchased and there have been zero shares sold by insiders this year.

Financials

Retrocom REIT reported the second-quarter financial results on August 8 with the following highlights:

Revenue	$22.8 million
Funds from operations	$6.7 million
Cash	$31.6 million
Debt	$561.1 million

Competition

Retrocom REIT's competitors include Riocan REIT (TSX:REI.UN), Crombie REIT (TSX:CRR.UN), and Morguard REIT (TSX:MRT.UN).

Here is a table of these competitors' insider-trading activities during the last six months.

Company	Insider buying / shares	Insider selling / shares
REI.UN	17,107	242,491
CRR.UN	105,272	2,200
MRT.UN	185,020	0

Only Retrocom REIT has seen intensive insider buying during the last 30 days.

Conclusion

There have been three different insiders buying Retrocom REIT and there have not been any insiders selling Retrocom REIT during the last 30 days. Two of these three insiders increased their holdings by more than 10%.

Retrocom REIT has a book value of $5.40 per share and the stock has a dividend yield of 9.3%. I believe the stock could be a good pick below the book value of $5.40 per share based on the intensive insider buying.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Top 10 Biotech Stocks To Invest In 2014

After an incredible performance in late March, when shares of Acadia Pharmaceuticals (NASDAQ: ACAD  ) jumped up 23%, they have once again exploded today, up 40% intraday. What's behind these massive leaps for this pharmaceutical company, and is there more on the way? In this video, Motley Fool health-care analyst David Williamson tells investors about the drug that has Acadia investors so excited, why it has so many competitive advantages, and what investors need to watch from here.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.�Click here now�to keep reading.

Top 10 Biotech Stocks To Invest In 2014: Osiris Therapeutics Inc.(OSIR)

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. It operates in two business segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. This segment focuses on developing biologic products for use in surgical procedures. The company?s lead biologic drug candidate is Prochymal, which is in phase 2 and 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes, pulmonary disease, and gastrointestinal injury resulting from radiation exposure. Its biologic drug candidates also include Chondrogen, a preparation of adult mesenchymal stem cells that is in phase 2 clinical trials for osteoarthritis and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen in various countries except in the United States and Canada. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Advisors' Opinion:

• [By Maxx Chatsko]

  Additionally, stem cell therapies have remained elusive as the industry's ultimate Holy Grail. Osiris (NASDAQ: OSIR  ) received Canadian approval for the world's first stem cell drug, Prochymal, for children battling acute graft-versus-host disease, or GvHD, last year. The approval meant more symbolically than to the bottom line, but it definitely put the potential of stem cells front and center for investors.

• [By Lauren Pollock]

  Osiris Therapeutics Inc.(OSIR) said Friday a proposed ruling from the Centers for Medicare and Medicaid Services won’t immediately affect reimbursements for its Grafix stem-cell product. The regenerative medicine company said Grafix will maintain its current reimbursement status — also called transitional pass-through status — potentially through late 2015.

• [By Alexander Maxwell]

  One of the companies attempting to develop a better treatment for chronic diabetic foot ulcers is Osiris Therapeutics� (NASDAQ: OSIR  ) . Earlier this month, Osiris shares more than doubled as the company announced positive data for its CDFU drug Grafix. The study results were very impressive to say the least; the study was stopped early due to the overwhelming efficacy exhibited by the treatment. A main highlight is the fact that 62% of Grafix patients had their wound closed at 12 weeks, compared to only 21% of patients using conventional methods. Clearly, the efficacy in this endpoint was overwhelming. Grafix also achieved all of the secondary endpoints for the trial, and more importantly demonstrated a relatively benign safety record.�

Top 10 Biotech Stocks To Invest In 2014: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Top Warren Buffett Stocks To Buy Right Now: Sanofi(SNY)

sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.

Advisors' Opinion:

• [By Brian Orelli]

  And Aegerion has to compete with Sanofi (NYSE: SNY  ) and Isis Pharmaceuticals' (NASDAQ: ISIS  ) Kynamro, which is approved for the same genetic disorder. Juxtapid is arguably a better drug with a better side-effect profile. It can also be taken orally, while Kynamro needs to be injected. Still, I think it's unreasonable to expect Aegerion to capture the entire market.

Top 10 Biotech Stocks To Invest In 2014: Regeneron Pharmaceuticals Inc.(REGN)

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.

Advisors' Opinion:

• [By Smith On Stocks]

  The Tethadur technology is potentially applicable to any biological drug and may have a significant opportunity in the development of biosimilars to current large selling products; it may improve the performance of those drugs through sustained release. Of particular interest is that pSivida has said that it has a fully funded agreement with a major biotechnology company to evaluate the potential for sustained release of a major product to the back of the eye. The initial agreement is for the pre-clinical setting. pSivida has not said what the drug is, but speculation naturally centers on Regeneron's (REGN) Eylea or Roche's (RHHBY.OB) Lucentis. These drugs are enormously successful for the treatment of "wet" AMD but must be must be injected into the eye on a monthly or six week time frame.

Top 10 Biotech Stocks To Invest In 2014: InterMune Inc.(ITMN)

InterMune, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies in pulmonology and fibrotic diseases. In pulmonology, the company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It markets pirfenidone, an orally active drug that inhibits the synthesis of TGF-beta under the Esbriet name in the European Union, as well as in a Phase III clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the Pirespa trade name. The company?s research programs focus on the discovery of small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of biotechnology company Intermune (NASDAQ: ITMN  ) surged 13% today after its quarterly results and outlook topped Wall Street expectations.

Top 10 Biotech Stocks To Invest In 2014: Rexahn Pharmaceuticals Inc (RNN)

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.

Archexin

Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.

Serdaxin

Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.

Zoraxel

Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.

The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.

Advisors' Opinion:

• [By Roberto Pedone]

  One under-$10 biopharmaceutical player that's just starting to move into breakout territory is Rexahn Pharmaceuticals (RNN), which is engaged in the development of novel treatments for cancer to patients. This stock has been on fire so far in 2013, with shares up sharply by 62%.

  If you take a look at the chart for Rexahn Pharmaceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of 36 cents per share to its intraday high of 53 cents per share. During that uptrend, shares of RNN have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RNN into breakout territory above some near-term overhead resistance levels at 49 cents to 50 cents per share. It's worth noting that volume today is tracking in extremely strong with over 3 million shares traded, versus its three-month average action of 1.22 million shares.

  Traders should now look for long-biased trades in RNN if it manages to break out above Thursday's intraday high of 53 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.22 million shares. If that breakout hits soon, then RNN will set up to re-test or possibly take out its next major overhead resistance levels at 64 cents to its 52-week high at 66 cents per share. Any high-volume move above 66 cents to 67 cents per share could then send RNN towards its next major overhead resistance levels at 81 cents per share.

  Traders can look to buy RNN off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at 47 cents per share. One can also buy RNN off strength once it clears 53 cents per share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Biotech Stocks To Invest In 2014: Multicell Technologies Inc (MCET)

MultiCell Technologies, Inc., incorporated on April 28, 1970, is a biopharmaceutical company. The Company is engaged in developing novel therapeutics and discovery tools to address unmet medical needs for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology and peripheral vessel applications. The Company�� portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, a Phase II therapeutic candidate for the treatment of PMSF, which has demonstrated efficacy in a 138-patient Phase IIa clinical trial; MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers, such as those expressing TLR-3; MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers, and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

MultiCell is pursuing research and development targeting degenerative neurological diseases, including multiple sclerosis (MS) and cancer. The Company�� therapeutics business addresses significant unmet medical needs for the treatment of neurological disorders and cancer through modulation of the innate and adaptive immune response. The Company�� therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver; control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as the Toll-like Receptors (TLRs), RIG-I-like receptor (RLR), and Melanoma Differentiation-Associated protein 5 (MDA-5) signaling; generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology; and modulate the noradrenaline-adrenaline neurotransmitter pathway.

The Com! pany�� medical device development platform is based on the design a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. The Company�� Ideal BioStent is a stent incorporating salicylate, the active component in aspirin, directly into the polymer chain. The Ideal BioStent also incorporates Sirolimus (rapamycin) in addition to salicylate, providing anti-restenotic therapy similar to commonly used drug-eluting metal stents.

MCT-125 for the treatment of fatigue in patients with multiple sclerosi

Fatigue is the most common symptom in MS. Overall, greater than 75% of persons with MS report having fatigue, and 50% to 60% report it as the worst symptom of their disease. The Company exclusively licensed the drug candidate LAX-202 from Amarin Neuroscience Limited (Amarin) for the treatment of fatigue in patients suffering from MS.

MCT-465, MCT-475 and MCT-485 for the treatment of cancer

MCT-465, MCT-475, and MCT 485 are in preclinical development, and are being investigated as prospective treatments for primary liver cancer and triple negative breast cancer. MCT-465 is a high molecular weight synthetic dsRNA (polyA:polyU, of 70bps) with immune-enhancing properties. MCT-485 is a low molecular weight synthetic dsRNA (polyA:polyU of 5bps) with direct tumor cytolytic properties. MCT-475 is a chimeric recombinant therapeutic antibody molecule that carries tumor-associated antigen peptide recognition in its complimentary determining region (CDR).

Top 10 Biotech Stocks To Invest In 2014: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headquartered in Fost er City, California.

Advisors' Opinion:

• [By Keith Speights]

  A major factor in the improvement in reducing deaths associated with HIV has been the ongoing development of antiretroviral drugs. Gilead Sciences (NASDAQ: GILD  ) stands as the leader in this market. Its Atripla, a combination of three Gilead HIV drugs, generated nearly $3.6 billion in sales last year. One of Atripla's component drugs, Viread, made more than $848,000 in 2012.

• [By Keith Speights]

  Another issue is fear over potential rivals. Gilead Sciences (NASDAQ: GILD  ) , for example, reported in May that its�idelalisib produced significant tumor shrinkage in half of the patients involved in an early-stage trial. Dr.�Sandra Swain, president of the American Society of Clinical Oncology, called the results "pretty incredible." Gilead is also testing�idelalisib in the treatment of�non-Hodgkin's lymphoma.

Top 10 Biotech Stocks To Invest In 2014: Oxford BioMedica PLC (OXB)

Oxford BioMedica plc is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines. The Company�� LentiVector platform products include ProSavin, RetinoStat, StarGen, UshStat, EncorStat, Glaucoma-GT and MoNuDin. Its 5T4 Tumour Antigen produces TroVax and Anti-5T4 antibody. The Prime Boost�� product includes Hi-8 Mel. Its GDEPT platform produces MetXia and Anti Angiogenesis platform produces EndoAngio-GT. The Company is developing four LentiVector platform product candidates for the treatment of ocular diseases: RetinoStat for wet age-related macular degeneration (AMD); StarGen for Stargardt disease; UshStat for Usher syndrome type 1B, and EncorStat for corneal graft rejection. TroVax is a therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen. On February 25, 2011, the Company purchased a freehold property, United Kingdom comprising a manufacturing facility.

Top 10 Biotech Stocks To Invest In 2014: Vertex Pharmaceuticals Incorporated(VRTX)

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Keith Speights]

  Here's another angle: Learn from successful companies. In other words, see what made a given company do well in the market and find others that exhibit similar attributes. There are plenty of companies to choose from, but let's see how this approach plays out with an example from the biotech world:�Vertex Pharmaceuticals (NASDAQ: VRTX  ) . Here are three investment strategy lessons from Vertex's success.

• [By Sean Williams]

  Vertex Pharmaceuticals (NASDAQ: VRTX  ) suffered through an unpleasant week, with shares down 9% after it announced a partial clinical hold on Friday for its all-oral hepatitis-C drug, VX-135. The drug, which is currently in midstage trials, was placed on clinical hold by the FDA after it noted elevated, but reversible, liver enzyme levels in patients receiving the 400mg dose with ribavirin. To me this looks like a precautionary hold, but it will be perceived as painful, since it puts Vertex's oral hepatitis-C medication that much further behind its competition. Kalydeco is becoming the future of Vertex with regard to its potential to treat various mutations of cystic fibrosis, so I wouldn't worry too much about this minor setback with VX-135.

• [By Brian Orelli]

  Vertex Pharmaceuticals (NASDAQ: VRTX  ) had the exact same wording -- maybe their flack went to the same law school -- in the announcement that the FDA had given�Breakthrough Therapy Designation to its cystic fibrosis drug Kalydeco as both a monotherapy and in combination with VX-809.

4 ways and more to start on a methodical savings plan!

In this era of recession, deflation, and job cuts, it is especially important for you to consider where your hard-earned money is going; financial security is the key in today�s unpredictable world. And the first step towards gaining that security is to have a Saving Plan.

Still not convinced? Then ask yourself why you need to save. The answer�s really very simple: so that your money can start earning money, and work towards reducing the effort you put in everyday.

Start saving now: Here's how!

You might wonder how to begin saving if your income is already over-committed. Efficiency and discipline are the answers.

�    You need to first find out where your income is going. Maintain a diary for the month, noting down everything you spend on, to the last paisa. You will be surprised at the amount of random purchases you make � from coffee breaks to grocery bills. These are the best places to start trimming.

�    Then, make a budget. This isn�t as difficult as you think. All a budget does is create a plan for spending, by stating expenses and goals. Make sure to cover fixed and regular expenses such as mortgage or rent, utility payments, and car or loan/credit card payments. Then set limits on necessities like groceries and clothing, as well as nice-to-haves like entertainment and travel. It�s also important at this stage to factor in a savings amount.

�    Now, your first priority is an emergency fund, if you don�t already have one in place. And the easiest way to do this is to have the amount deducted from your salary every month and put into a Fixed or Recurring Deposit. Give yourself a pat on the back if you find yourself adding that little extra to your fund because you managed to save a little more this month. You might find it easier to stay within budget if you use cash or debit cards for the necessities and frills.

�    As your emergency fund accumulates, your next task is to find more money for savings and even investment. Begin by paying off your credit cards. If you spend a little time examining your monthly statements, you will be amazed to see how much money you�re losing just by way of interest!

Saving Vs. Investing

At this point, we need to address the differences between saving and investing.

Savings provide for emergencies and fund specific purchases in the near future (within two years). The primary goal is to store funds and keep them safe. However, you invest to increase net worth and work toward long-term goals. Also realise that investing involves risk, where you could lose some of your original investment. Only consider an investment plan when you have in place an emergency fund, insurance, control over credit use, and a retirement plan.

In the long run

Now, consider making a long-range savings and investment plan. When beginning to plan for investments, consider your goals, the amount of time you will be able to spend on nurturing these investments, how much you know about the funds, how much money you have to invest, whether you can tolerate risk, and handle loss. Remember that your ultimate goal is a financially secure future for you and your family.

If you look back over all that we�ve discussed so far, you will realise that we�ve told you how to begin saving money, in small, manageable chunks. The final objective might be to set aside enough for you to retire so that you don�t have to work another day, but your immediate goal is to start the process and become habituated, so that saving becomes a way of life, and a chance to improve how you live.

Content partner:

BankBazaar.com is an online marketplace where you can instantly get the lowest loan rates , compare
and apply online for your personal loan , home loan , car loan and credit card from India's leading banks and NBFCs

Disclaimer: While we have made efforts to ensure the accuracy of our content (consisting of articles and information), neither this website nor the author shall be held responsible for any losses/ incidents suffered by people accessing, using or is supplied with the content.

What Is The Barron’s 400 Index And How Does It Work?

In the ETF industry's relatively short history, investors have witnessed a slew of one-of-a-kind products hit the Streets; from plain vanilla funds to ETFs that utilize unique screening methodologies, investors can now choose from more than 1,400 different options. Carlos Dies, President of investment-research firm MarketGrader, recently took the time to discuss the compelling strategy behind the new Barron's 400 ETF (BFOR), which aims to provide investors exposure to "America's most promising stocks" . 

ETF Database (ETFdb): What was the inspiration behind creating the Barron's 400 Index?

Carlos Diez (CD): MarketGrader actually created its first index, MG40, in 2003, several years before we created the Barron's 400. At the time our research service was brand new and nobody knew us or our methodology, so we thought that the best way to show our clients whether MG worked was by putting our research to the test in a model portfolio. MG40 did very well (it helped that the stock market did very well in 2003) and we gained our first institutional client in the asset management space.

As we began to develop other MarketGrader indexes we thought there would be investor interest for a broad index that could compete against some of the traditional broad market benchmarks. Around that same time we had developed a research and content sharing agreement with Barron's, since they saw in our grading methodology some of the attributes they watched closely when picking the companies they write about. It quickly became clear that we could collaborate in developing a broad index that selected what they called the "most promising companies in America"  .

ETFdb: What is the methodology behind the B400 and how does it actually work?

CD: MarketGrader rates almost 6,000 North American stocks; virtually everything listed in the U.S. and Canada (except pink sheet stocks). We do this daily, even though few things change in the underlying grades and rating of every c! ompany; nevertheless, we do it daily to ensure all the latest stock prices are included in the valuation portion of our analysis.

Here's where it's important to differentiate between our individual grading process and the index rebalance schedule. The grades are, as explained above, calculated daily while the index, in this case B400, is rebalanced twice a year. So here's how the grading works:

MarketGrader calculates for each stock 24 individual fundamental indicators across four categories:

GrowthValueProfitabilityCash FlowEach category has six indicators and each one of those is assigned a letter grade between A+ and F. A numerical grade is also assigned to each indicator depending on the letter grade. All 24 indicators are then aggregated into a final numerical grade that ranges between zero (0) and one hundred (100). Thus, if a company had an A+ in each of the 24 indicators it would get a perfect score of 100. Our rating is assigned depending on this score. Anything above 60 is rated 'Buy,' while 50-59 represents a 'Hold' rating and anything 49 and below is rated 'Sell.' To give you an idea of how rigorous our grading system is, as of this morning our coverage universe was broken down into 16% Buys, 16% Holds and 68% Sells. This isn't far from the historical mean.

Now to the index: on the third week of March and September, MarketGrader picks the top 400 grades based on the process described above in order to build the index. However, it applies a few other rules to ensure the index is well balanced and that its underlying components are liquid enough. First of all, only companies with a float-adjusted market cap of at least $250 million are eligible. It also ensures that all selected stocks have a minimum 3-month dollar based avg. daily volume of $2 million. Finally, it makes sure that no more than 20% of all selections (or 80 stocks) belong in the same economic sector. The resulting 400 stocks are equally weighted and this becomes the Barron's 400 ! Index .
ETFdb: Why does it make sense to use the ETF wrapper for investors looking to pursue this sort of strategy?

CD: The ETF wrapper makes sense for several reasons. First of all, the creation/redemption mechanism facilitates the rebalance process in a very tax-efficient way. It also ensures that fund shareholders aren't penalized in terms of taxes when others redeem; it also allows the fund to stay fully invested without having to hold large cash positions. From a marketing and transparency standpoint the ETF structure is ideal because obviously anyone with a brokerage account can buy the ETF once it goes live. The fund advisor doesn't have to jump through all kinds of hoops to make sure it gets approved on all sorts of platforms.

ETFdb: There are some out there who believe ETFs have gone too far from their initial intention of offering broad-based exposure to buy-and-hold investors. What's your take on the innovation in the ETF industry over the last several years?

CD: I would say that in some cases that's accurate but not in others. I think the original intention of the ETF structure was to give institutions a highly efficient and inexpensive vehicle to gain exposure to a given market. With time individual investors caught on to its benefits, which only helped to expand the structure's popularity. As more sponsors developed new ETFs, they opened new markets and new asset classes to investors in a way few dreamed of only 20 years ago. And they did so very inexpensively for the investor. All of this has been extremely positive .

However, as in any growth market, it's normal that you get investors trying to participate in the trend, who then start devising products to launch just for the sake of launching them. You then get a case of the tail wagging the dog, where sponsors decide to launch an ETF as step one of their plan and then they try to identify an index, asset class, geography, niche or strategy to track. But the market is self-correcting and so event! ually pro! ducts make it or not based on their own merit.

Bottom Line: For those looking to invest in the most fundamentally sound companies with the most attractively priced shares, the new Barron's 400 ETF (BFOR) is certainly a compelling option. Considering that the Barron's 400 list has consistently outperformed leading stock indexes, the ETF wrapper has now allowed investors to easily and cost-effectively tap into what may be "America's most promising stocks."

Disclosure: No positions at time of writing.

Top Low Price Companies To Buy Right Now

With shares of Wal-Mart (NYSE:WMT) trading around $77, is WMT an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Wal-Mart operates retail stores in various formats around the world. The company aims to price items at the lowest price every day. Wal-Mart operates in three business segments: the Walmart U.S. segment, the Walmart International segment, and the Sam�� Club segment. It operates retail stores, restaurants, discount stores, supermarkets, supercenters, hypermarkets, warehouse clubs, apparel stores, Sam��� Clubs, neighborhood markets, and other small formats, as well as Walmart.com and Samsclub.com. Through its retail channels, Wal-Mart is able to provide a variety of products and services at very affordable prices to consumers and companies worldwide.

Wal-Mart is an especially hot place for summer lovers to take advantage of, as it provides a one-stop shop for anything a beach bum�� heart desires.�Customers know that they can get in and out of Wal-Mart quickly and find all of their summer gear at relatively low prices.�One out of three customers give Wal-Mart�� summer products a perfect 10, and 33.8 percent assert that they would be extremely likely to recommend the store. Wal-Mart is undoubtedly looking at a very successful summer sales quarter.�For consumers and businesses looking for one location that contains a wide variety of products and services, Wal-Mart is the spot and will continue to be well into the future.

Top Low Price Companies To Buy Right Now: Cwt Limited (C14.SI)

CWT Limited, together with its subsidiaries, provides integrated logistics solutions worldwide. The company engages in warehousing, transportation, freight forwarding and cargo consolidation, collateral management, surface preparation of metal materials for corrosion control, and container depot operations. It is also involved in the design, building and construction management, maintenance, and repair of vehicles, equipment, and buildings. The company also provides management and maintenance services for facilities; and design and building services for logistics properties, as well as supplies and installs engineering products. In addition, the company engages in the trade and supply chain management of base metal non-ferrous concentrates with a focus on copper, lead, zinc, and other minor metals, as well as energy products, such as coal and fuel. Further, CWT Limited provides financial services, including asset management services and brokering services for futures and d erivatives trades; and is involved in property management business. It serves customers in the commodities, chemical and petrochemical, marine, oil and gas, defense, and industrial sectors. The company was founded in 1970 and is headquartered in Singapore.

Top Low Price Companies To Buy Right Now: Ultra Clean Holdings Inc.(UCTT)

Ultra Clean Holdings, Inc., together with its subsidiaries, engages in the design, development, engineering, manufacture, and sale of critical modules and subsystems primarily to original equipment manufacturers in semiconductor capital equipment, flat panel, medical, energy, and research industries. It offers gas delivery systems that control the flow, pressure, sequencing, and mixing of specialty gases into and out of the reaction chambers of semiconductor manufacturing tools; chemical mechanical planarization modules; chemical delivery modules, which deliver gases and reactive chemicals from a centralized subsystem to the reaction chamber; and top-plate assemblies that form the top portion of the reaction chamber. The company also provides frame assemblies that form the support structure to which other assemblies are attached and include pneumatic harnesses and cables that connect other critical subsystems together; process modules, which are subsystems of semiconductor manufacturing tools that process integrated circuits onto wafers; and other high level assemblies for use in semiconductor manufacturing, research, flat panel, energy, and medical equipment industries. It sells its products through its direct sales force primarily in North America, Asia, and Europe. Ultra Clean Holding, Inc. was founded in 1991 and is headquartered in Hayward, California.

Top Oil Stocks To Buy Right Now: Vertex Pharmaceuticals Incorporated(VRTX)

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Sean Williams]

  One of today's FDA-approved treatments is�Vertex Pharmaceuticals' (NASDAQ: VRTX  ) Incivek, which is an oral medication administered with ribavirin and a type of interferon called�peginterferon alfa. While relatively effective, interferon can cause lingering flu-like symptoms in patients for up to 48 weeks, which can make the side-effects of the medication as unpleasant as the chronic HCV disease is itself. However, new drugs are currently in the works which could change all that.

Top Low Price Companies To Buy Right Now: Wright Express Corporation(WXS)

Wright Express Corporation provides business payment processing and information management solutions in North America, the Asia Pacific, and Europe. It operates in two segments, Fleet Payment Solutions and Other Payment Solutions. The Fleet Payment Solutions segment offers payment and transaction processing, and account and information management services to commercial and government fleets. This segment markets its products and services directly and indirectly through co-branded, affinity, distributor, or private label relationships. The Other Payment Solutions segment provides payment processing solutions for corporate purchasing and transaction monitoring needs. This segment?s products include corporate charge cards that provide commercial travel and entertainment, and purchase capabilities to businesses; and single use account that allow businesses to use for transactions where no card is presented. This segment markets its products and services directly to commercial and government organizations; and brand stores, government departments, and service organizations. The company was founded in 1983 and is headquartered in South Portland, Maine.

Top Low Price Companies To Buy Right Now: Ferrellgas Partners L.P. (FGP)

Ferrellgas Partners, L.P. engages in the distribution and sale of propane, and related equipment and supplies primarily in the United States. It transports propane to propane distribution locations, tanks on customers� premises, or to portable propane tanks delivered to retailers. The company conducts its portable tank exchange operations under the Blue Rhino brand name through a network of independent and partnership-owned distribution outlets. The company�s propane is primarily used for space heating, water heating, cooking, outdoor cooking using gas grills, crop drying, irrigation, weed control, and other propane fueled appliances; as an engine fuel for power vehicles and forklifts; and as a heating or energy source in manufacturing and drying processes. It serves approximately 1 million residential, industrial/commercial, portable tank exchange, agricultural, wholesale, and other customers in 50 States, the District of Columbia, and Puerto Rico. As of July 31, 2012, it had 924 propane distribution locations. The company also engages in the wholesale marketing of propane appliances; sale of refined fuels; and provision of common carrier services. Ferrellgas Partners, L.P. was founded in 1939 and is headquartered in Overland Park, Kansas.

Advisors' Opinion:

• [By Dan Caplinger]

  Ferrellgas Partners (NYSE: FGP  ) will release its quarterly report on Friday, and shares of the propane distributor have jumped to two-year highs recently. Yet with a somewhat different exposure to the industry than rivals AmeriGas (NYSE: APU  ) and Suburban Propane (NYSE: SPH  ) , will Ferrellgas earnings be able to grow enough to make optimistic investors satisfied?

• [By Dan Caplinger]

  On Thursday, Ferrellgas Partners (NYSE: FGP  ) will release its latest quarterly results. The master limited partnership might not be in the glamorous part of the energy space, but that hasn't held it back from posting good returns for investors.

• [By Rich Duprey]

  Propane gas provider�Ferrellgas Partners� (NYSE: FGP  ) �announced yesterday�its third-quarter dividend of $0.50 per share, the same rate it's paid every quarter for the last 75 quarters.

Top Low Price Companies To Buy Right Now: CNOOC Limited(CEO)

CNOOC Limited, through its subsidiaries, engages in the exploration, development, production, and sale of crude oil, natural gas, and other petroleum products. The company?s oil and natural gas properties are located in offshore China, which include Bohai Bay, western south China Sea, eastern south China Sea, and east China Sea, as well as in Indonesia, Iraq, and other regions in Asia; and Oceania, Africa, North America, and South America. As of December 31, 2010, the company had net proved reserves of approximately 2.99 billion barrels-of-oil equivalent, including approximately 1.92 billion barrels of crude oil and 6,458.3 billion cubic feet of natural gas. It also provides bond issuance services; and has a joint venture with Bridas Energy Holdings. CNOOC Limited was founded in 1982. The company is headquartered in Central, Hong Kong, and is considered a Red Chip company due to its listing on the Hong Kong Stock Exchange. CNOOC Limited is a subsidiary of China National Of fshore Oil Corporation.

Advisors' Opinion:

• [By Jim Jubak]

  The auction news isn't good for investors in Brazil's Petrobras (PBR), but it could well be a boon for China and Chinese oil companies such as PetroChina (PTR) and CNOOC (CEO).

• [By Jonathan Yates]

  As to be expected, the share price has drifted down from the peak after the bullish activity. But long term investors should take note of the resources owned by Octagon 88. Canadian energy assets have drawn "Big Oil" from around the world such as CNOOC (NYSE: CEO) and Chevron (NYSE: CVX). In addition, Suncor Energy (NYSE: SU), a major oil firm based in Canada, has Warren Buffett gobbling up its shares.

• [By Arjun Sreekumar]

  Notable foreign joint ventures
  The practice has been quite common among foreign companies engaging in joint ventures with U.S. firms. For instance, the use of a drilling carry was a feature of Chesapeake Energy's (NYSE: CHK  ) transaction with China's largest energy company, CNOOC (NYSE: CEO  ) , back in 2010, though it was noticeably absent from its most recent joint venture agreement with Sinopec (NYSE: SHI  ) .

Top Low Price Companies To Buy Right Now: Glacier Bancorp Inc. (GBCI)

Glacier Bancorp, Inc., a multi-bank holding company, provides commercial banking services in Montana, Idaho, Wyoming, Colorado, Utah, and Washington. It offers transaction and savings deposits; real estate, commercial, agriculture, and consumer loans; mortgage origination services; and retail brokerage services to individuals, small to medium-sized businesses, community organizations, and public entities. The company�s deposit products include non-interest bearing demand accounts, interest bearing checking accounts, regular statement savings accounts, money market deposit accounts, fixed rate certificates of deposit, negotiated-rate jumbo certificates, individual retirement accounts, and reciprocal deposits. Its loan products comprise construction and permanent loans on residential real estate; consumer land and lot acquisition loans; unimproved land and land development loans; residential builder guidance lines comprising pre-sold and spec-home construction, and lot acqu isition loans; commercial real estate loans to purchase, construct, and finance commercial real estate properties; commercial and industrial loans; consumer loans secured by real estate, automobiles, and other assets; second mortgage and home equity loans; and agriculture loans. The company operates 106 locations, including 97 branches. Glacier Bancorp, Inc. was founded in 1955 and is headquartered in Kalispell, Montana.

Advisors' Opinion:

• [By Eric Volkman]

  Glacier Bancorp (NASDAQ: GBCI  ) is reaching into its vault for more cash to return to shareholders. The company this week declared its latest dividend, which is to be $0.15 per share paid on July 18 to shareholders of record as of July 9.

Top Low Price Companies To Buy Right Now: Community Bank Shares of Indiana Inc.(CBIN)

Community Bank Shares of Indiana, Inc. operates as a bank holding company for Your Community Bank (YCB) and The Scott County State Bank (SCSB) that provide personal and business banking services in Indiana and Kentucky. Its deposit products include non-interest and interest-bearing checking accounts, savings accounts, money market accounts, certificates of deposit, and individual retirement accounts. The company also offers various loan products comprising commercial business loans, commercial real estate loans, residential real estate loans, and construction loans, as well as consumer loans, such as home equity lines of credit, auto loans, home improvement loans, and loans secured by deposit accounts. In addition, it also offers non-deposit investment products, which include stocks, bonds, mutual funds, and annuities. The company, through its subsidiary, YCB, provides its services through operating a main office and 11 branch offices in Clark and Floyd Counties, Indiana; and 5 branch offices in Jefferson and Nelson Counties, Kentucky, as well as through its subsidiary, SCSB, operates main office and 3 branch offices in Scott County, Indiana. Community Bank Shares of Indiana, Inc. was founded in 1937 and is headquartered in New Albany, Indiana.

Top Canadian Stocks To Buy For 2014

No investor will ever forget the financial crisis of 2008-2009. However, some might not be fully-aware of the lessons to be learned from it, writes Rob Carrick of the Globe and Mail.

Here are four investing lessons we've learned since the global financial crisis hit with full-force five years ago:

1. You need five years in the market, but ten is better.

No matter how hard they fall, the stock markets always come back. They rebounded from the tech wreck in 2000-01, and they did likewise after the more frightening crash of 2008-09. But only now, five years later, is the Canadian stock market starting to get any traction in exceeding its pre-crash high water mark.

That's why a five-year rule is mandatory when investing in stocks. If you can't hold that long, don't buy. Ten years is a much better minimum hold period. While the S&P/TSX composite index gained just 1.3% annually on average over the five years to August 31, the 10-year gain was 8.1%. Both numbers are total returns, which means dividends and share price gains are combined.

Top Canadian Stocks To Buy For 2014: Abbott Laboratories(ABT)

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The company offers adult and pediatric pharmaceuticals for rheumatoid and psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease; dyslipidemia; HIV infection; prostate cancer, endometriosis and central precocious puberty, and anemia caused by uterine fibroids; respiratory syncytial virus; adult males who have low or no testosterone; secondary hyperparathyroidism; hypothyroidism; and pancreatic exocrine insufficiency, as well as anesthesia products. It also provides diagnostic products, such as immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-b ased tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. In addition, the company offers a line of pediatric and adult nutritional products. Further, it provides coronary, endovascular, vessel closure, and structural heart devices, such as drug-eluting stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, carotid stent systems, percutaneous valve repair systems, and drug eluting bioresorbable vascular products. Additionally, the company provides blood glucose monitoring meters, test strips, data management software, and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, lasik surgery, contact lens, and dry eye products, as well as branded generic pharmaceutical products. Abbott primarily serves retailers, wholesalers, hospitals, and health care facilities. Abbott was founded in 1888 and is headquartered in Abbott Park, Illinois.

Advisors' Opinion:

• [By Rich Smith]

  Don't look now, but Abbott Labs (NYSE: ABT  ) is about to buy itself a bit of growth.

  On Monday, the Abbott Park, Ill.-based medical products giant announced that it has agreed to buy privately held medical device-maker IDEV Technologies for $310 million, net of cash and debt. In return, it will gain IDEV's portfolio of products that include, importantly, the SUPERA Veritas self-expanding nitinol stent system, used for opening blocked blood vessels. Approved for use in Europe, SUPERA Veritas has only limited approval for use in the U.S. but is in the process of seeking FDA approval for expanded usage.

Top Canadian Stocks To Buy For 2014: ENI S.p.A. (E)

Eni SpA, an integrated energy company, engages in the exploration, production, transportation, transformation, and marketing of oil and natural gas. The company also involves in the production and sale of electricity; refining and marketing of petroleum products; and production and sale of petrochemical products and hydrocarbons. In addition, it engages in the offshore and onshore hydrocarbon field construction. Further, the company offers offshore and onshore drilling, and offshore design and engineering services for oil and gas companies. It has a strategic partnership with Gazprom for the joint development of projects in the upstream oil and gas markets. Eni SpA operates in Europe, Africa, Asia and Oceania, and the Americas. The company was founded in 1953 and is headquartered in Rome, Italy with an additional office in San Donato Milanese, Italy.

Advisors' Opinion:

• [By Sean Williams]

  Despite operating around the globe, many of Chevron's assets are well-protected from political unrest or violence. The same can't be said for Italian-based Eni (NYSE: E  ) which saw a good chunk of its oil production come under serious pressure in 2011 because of civil unrest and an eventual regime change in Libya. At the time, 14% of Eni's daily production ��nearly 250,000 barrels ��came from Libya and it maintained quite a few other undeveloped assets in the country. Eni's prospects have since improved, but other oil and gas companies deal with the similar potential for unrest on a daily basis.

5 Best Biotech Stocks To Invest In Right Now: Potomac Electric Power Company(POM)

Pepco Holdings, Inc., through its subsidiaries, engages in the transmission, distribution, and supply of electricity. The company also distributes and supplies natural gas. It distributes electricity to approximately 1.8 million customers in the mid-Atlantic region and delivers natural gas to approximately 123,000 customers in Delaware. In addition, the company involves in the retail supply of electricity and natural gas; provision of energy efficiency services to federal, state, and local government customers; and designs, constructs, and operates combined heat and power and central energy plants, as well as owns and operates two oil-fired generation facilities. Further, it offers high voltage electric construction and maintenance services, low voltage electric construction and maintenance services, and streetlight construction and asset management services to utilities, municipalities, and other customers in the Washington, District of Columbia. Additionally, the company holds investments in eight cross-border energy leases. Pepco Holdings, Inc. was founded in 1896 and is based in Washington, District of Columbia.

Advisors' Opinion:

• [By Sean Williams]

  Powering up
  It's pretty rare for stocks in the electric utility sector to see a prolonged dip given that electricity is a necessity product, but that's what we've seen from Mid-Atlantic electric utility provider Pepco Holdings (NYSE: POM  ) .

Top Canadian Stocks To Buy For 2014: Grupo TMM S.A.(TMM)

Grupo TMM, S.A.B., together with its subsidiaries, operates as an integrated logistics and transportation company in Mexico. The company offers maritime transportation services, including offshore vessels, which offer transportation and other services to the Mexican offshore oil industry; tankers that transport petroleum products in Mexican waters; parcel tankers, which transport liquid chemical and vegetable oil cargos from and to the United States and Mexico; and tugboats that provide towing services at the port of Manzanillo, Mexico. It operates a fleet of 46 vessels, which comprise product and chemical tankers, harbor tugs, and various offshore supply vessels. The company also operates two Mexican port facilities, Tuxpan and Acapulco, as well as provides port agent services to vessel owners and operators in the Mexican ports. Its logistics business provides trucking services to manufacturers consisting of automobile plants, and retailers, as well as offers logistical f acilities in industrial cities and railroad hubs in Aguascalientes, Toluca, Puebla, Veracruz, Nuevo Laredo, Cuernavaca, Mexico City, Monterrey, Manzanillo, Ensenada, and Altamira. The company's logistics services include consulting, analytical, and logistics outsourcing; logistics network analysis; logistics information process design; trucking, intermodal transport, and auto haulage services; warehousing and bonded warehousing facility management; supply chain and logistics management; product handling and repackaging; local pre-assembly; maintaining and repairing containers; and inbound and outbound distribution using truck transport. Grupo TMM was founded in 1955 and in headquartered in Mexico City, Mexico.

Top Canadian Stocks To Buy For 2014: Spectrum Brands Holdings Inc.(SPB)

Spectrum Brands Holdings, Inc., together with its subsidiaries, operates as a consumer products company worldwide. It offers consumer batteries, including alkaline and zinc carbon batteries, rechargeable batteries and chargers, and hearing aid batteries and other specialty batteries; pet supplies, such as aquatic equipment and supplies, dog and cat treats, small animal foods, clean up and training aids, health and grooming products, and beddings; and home and garden control products comprising household insect controls, insect repellents, and herbicides. The company also provides electric shaving and grooming devices; small appliances, including small kitchen appliances and home product appliances; electric personal care and styling devices; and portable lighting. Its sells its products through various trade channels, including retailers, wholesalers and distributors, hearing aid professionals, industrial distributors, and original equipment manufacturers primarily under t he Rayovac, Remington, Varta, George Foreman, Black & Decker, Toastmaster, Farberware, Tetra, Marineland, Nature?s Miracle, Dingo, 8-in-1, Littermaid, Spectracide, Cutter, Repel, Hot Shot, Black Flag, and TAT brands. The company was headquartered in Madison, Wisconsin. As of January 7, 2011, Spectrum Brands Holdings, Inc. operates as a subsidiary of Harbinger Group Inc.

Third Avenue Management Comments on Dundee Corporation

During the quarter the Fund established a meaningful position in shares of Dundee Corporation (TSX:DC.A), a Toronto-based holding company run by founder Ned Goodman. Having cut his teeth in investing at Brookfield Asset Management's predecessor company in the 1960s and Beutel Goodman which he co-founded in 1967, Goodman would go on to found Dundee in 1991. Goodman has been a magnificent allocator of capital at Dundee, building businesses and 11 investing in public and private companies. The uncertain macro backdrop post-Financial Crisis has given Goodman a penchant for hard assets rather than paper assets, resulting in a unique collection of investments, ranging from financial services and real estate to metals, mining, energy and agriculture businesses, including control of the largest organic beef operator in North America with more than 12,000 head of cattle. While past performance is no guarantee of future results, Dundee has generated an impressive 18% annualized return for its shareholders over the past twenty years.To understand Dundee requires a look past its income statement, where historical reported results are volatile and muddied by consolidated financials of entities no longer owned or consolidated, as well as gains on the sale of underlying securities and businesses, including the 2011 sale of a controlling stake in Dundee Wealth to Bank of Nova Scotia for C$1.4 billion and the spinout of a majority interest in Dundee Real Estate Company earlier this year. Today, Dundee's enterprise value is close to the value of its public securities holdings, net of a modest amount of debt. "Free" are the company's private investment portfolio and private subsidiaries, carried at book value, which together are close to half of Dundee's market value. While there is certainly an element of "key man risk," as any eventual successor will have enormous shoes to fill, we think hard asset values, values of publicly traded securities and a significant discount to our estimate of net asset value provide a ! meaningful margin of safety for the investment.We have followed Ned Goodman and Dundee for a number of years, as a like-minded operator and investor with significant ownership aligning his interests with those of his shareholders. The position reflects a true collaboration with our investment team colleagues. Vic Cunningham provided much of the recent legwork, while Ryan Dobratz offered key insights into the real estate assets and their valuations.Legg Mason is a premier mutual fund complex that dates back to the 1980s. While the firm has recently suffered significant asset outflows in the wake of subpar investment returns, the company has retained a strong franchise (with several well-known brands under its umbrella), a diversified asset mix, and a sound balance sheet. Under new leadership, the business appears to be on the mend and capital allocation continues to be favorable—management has repurchased $1.2 billion of shares in the past three years (shrinking the share count by more than 20%) and has been increasing the dividend. Moreover, the relative investment performance among its stable of investment managers is beginning to improve. While the company is still under-earning its potential in our view, its cash flows remain strong, aided by a large deferred tax asset resulting from net operating losses generated in prior periods. Fund management initiated its position in Legg Mason Common at an implied free cash flow yield of about nine percent, and we believe the company's cash flows could increase markedly in the near future if performance and asset flows continue to improve.From Dundee Corporation's fourth quarter 2013 commentary.

Also check out: Third Avenue Management Undervalued Stocks Third Avenue Management Top Growth Companies Third Avenue Management High Yield stocks, and Stocks that Third Avenue Management keeps buying

Currently 0.00/512345 Rating: 0.0/5 (0 votes)

Subscribe via Email Subscribe RSS Comments Please leave your comment:
More GuruFocus Links

Latest Guru Picks	Value Strategies
Warren Buffett Portfolio	Ben Graham Net-Net
Real Time Picks	Buffett-Munger Screener
Aggregated Portfolio	Undervalued Predictable
ETFs, Options	Low P/S Companies
Insider Trends	10-Year Financials
52-Week Lows	Interactive Charts
Model Portfolios	DCF Calculator
RSS Feed	Monthly Newsletters
The All-In-One Screener	Portfolio Tracking Tool

MORE GURUFOCUS LINKS

Latest Guru Picks	Value Strategies
Warren Buffett Portfolio	Ben Graham Net-Net
Real Time Picks	Buffett-Munger Screener
Aggregated Portfolio	Undervalued Predictable
ETFs, Options	Low P/S Companies
Insider Trends	10-Year Financials
52-Week Lows	Interactive Charts
Model Portfolios	DCF Calculator
RSS Feed	Monthly Newsletters
The All-In-One Screener	Portfolio Tracking Tool

TSX:DC.A STOCK PRICE CHART 18.56 (1y: -5%) $(function() { var seriesOptions = [], yAxisOptions = [], name = 'TSX:DC.A', display = ''; Highcharts.setOptions({ global: { useUTC: true } }); var d = new Date(); $current_day = d.getDay(); if ($current_day == 5 || $current_day == 0 || $current_day == 6){ day = 4; } else{ day = 7; } seriesOptions[0] = { id : name, animation:false, color: '#4572A7', lineWidth: 1, name : name.

Is Rockwell Medical (RMTI) Really a Sell? DVA, FMS & NXTM

Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA) and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM). 

What is Rockwell Medical?

Small cap Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency anemia, secondary hyperparathyroidism and hemodialysis. Rockwell Medical calls itself a leader in producing and delivering hemodialysis concentrates (solutions and powders) along with related ancillary products to dialysis providers located throughout the US and abroad. In addition, the company is further developing brand extensions and new drug opportunities in the areas of anemia for women's health, oncology, gastroenterology and parenteral nutrition, as well as new drugs for other targeted renal therapies and indications.

As for dialysis stock peers, DaVita Healthcare Partners is a provider of dialysis and administrative services; Fresenius Medical Care is a Germany-based vertically integrated holding and kidney dialysis company operating in the fields of dialysis products and dialysis services; and small cap NxStage Medical is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

What You Need to Know About or Be Warned About Rockwell Medical?

Brean Capital analyst Jonathan Aschoff initiated coverage on Rockwell Medical with a sell plus he commented that:

"Triferic did not appear to reduce total ESA use versus placebo in the PRIME trial, and did not reduce ESA use versus baseline, by contrast to what is seen with IV iron and Zerenex. The CRUISE trials had a questionable design that we view as unlikely to result in approval. Both CRUISE trials did not allow IV iron use or changes in ESA use, which is utterly inconsistent with current dialysis center practice under bundled reimbursement. More than 80% of the patients in all CRUISE arms did not complete the 48-week treatment period, making the primary endpoint evaluation period (defined as the last 1/6 of time on treatment) highly variable among patients. A key employee termination and resulting lawsuit further speaks to inadequate Triferic testing, in our view, where a former VP of Drug Development and Medical Affairs warned Rockwell that its Phase 2b trial did not adequately show efficacy or dose-ranging information to proceed directly to Phase 3."

Aschoff's sell rating and assertions have caused a reaction on StockTwits with someone noting a blog post from 2007 complaining about his "daily bashing of Provenge," a drug to help prostate cancer patients in the late stage of disease from Dendreon Corporation (NASDAQ: DNDN) which apparently works just fine (see the Wikipedia entry for the drug here). The blog post goes on to note that:

"He was caught impersonating a doctor in order to get confidential information a few years ago. Why respected publications such as Barrons and Forbes continue associate themselves with this medical impersonator is baffling to say the least."

The whole story can be found here in a Wall Street Journal article about biotech analysts like Aschoff using questionable tactics to peek into drug trial results – meaning one has to wonder what kind of information he may have obtained and how he obtained it.

With that said, Aschoff also commented:

"Sales of Rockwell's drugs have been stagnant ($60 million, $49 million, and $50 million in 2010, 2011, and 2012, respectively) and we project flat future growth."

A look at Rockwell Medical's financials does show flat revenues of $49.84M (2012), $48.97M (2011), $59.55M (2010) and $54.73M (2009) for the past four years along with increasingly large net losses of $54.02M (2012), $21.44M (2011), $2.68M (2010) and $5.50M (2009) plus $31.22M in cash and short term investments to cover $18.07M in current liabilities and $19.43M in long term debt. Those financials are something investors should consider but of course FDA approval of Triferic would change all of that (Note: Stifel Nicolaus analyst Annabel Samimy says annual sales of Triferic could reach $200 million a year).

Share Performance: Rockwell Medical vs. DVA, FMS & NXTM

On Monday, small cap Rockwell Medical rose 1.13% to $13.47 (RMTI has a 52 week trading range of $3.16 to $15.85 a share) for a market cap of $538.77 million plus the stock is up 67.3% since the start of the year and up 298.5% over the past five years. Here is a look at the long term performance of Rockwell Medical verses large cap dialysis stocks DaVita Healthcare Partners and Fresenius Medical Care plus small cap NxStage Medical:

As you can see from the above chart, small cap dialysis stock NxStage Medical peaked in January 2011 and has trended down since then while Rockwell Medical bottomed out before the summer. Meanwhile, large caps Fresenius Medical Care has been relatively flat and DaVita Healthcare Partners has been steadily trending upward.

Finally, here is a quick look at the technical charts for all four dialysis stocks:

The Bottom Line. Irrespective of what Brean Capital analyst Jonathan Aschoff says, his track record and any ulterior motives he may have (e.g. they are shorting the stock), its really the FDA that will make or break small cap dialysis stock Rockwell Medical. So stay tuned…

Jim Cramer's 6 Stocks in 60 Seconds: LLY GIS RRC FINL AXP YHOO (Update 1)

Check out Jim Cramer's latest trading recommendations on "Action Alerts Plus". (Updates from 11:13 a.m. ET with closing information.)

NEW YORK (TheStreet) -- Here's what Jim Cramer had to say on CNBC's "Squawk on the Street" Tuesday.

Based on a $65 price target, Eli Lilly (LLY) would appear "very inexpensive," Cramer said. But he doesn't think the company has a great product pipeline. LLY ended the day 3 cents higer at $49.22.

According to Cramer, people don't think General Mills (GIS) has natural and organic foods, which is "hurting" the stock. He noted Morgan Stanley considers GIS "challenged." GIS fell 33 cents to $49.58.

The fact that Range Resources (RRC) has failed to move higher on a positive note from Wells Fargo concerns Cramer. He suggested the oil and gas exploration industry has "run too much." RRC fell 41 cents to $79.76. Bank of America upgraded Finish Line (FINL) to buy from sell. Cramer said he'd "buy the stock" based partly on how well the brand is doing in Macy's (M) locations. FINL rose 1.9% to $25.89.

American Express  (AXP) recently reported some of its credit numbers, and Cramer suggested that AXP's likelihood was "very, very small" for a default. AXP is a holding in Cramer's charitable portfolio, Action Alerts PLUS. AXP fell 41 cents to $84.11. Citigroup raised its price target on Yahoo! (YHOO) to $46 from $39. Cramer said that when investors add up the value from all of YHOO's different business segments, it commands a premium valuation. YHOO fell nearly 1% to $39.51. To sign up for Jim Cramer's free Booyah! newsletter, with all of his latest articles and videos, please click here. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell

Stock quotes in this article: LLY, GIS, RRC, FINL, M, AXP, YHOO